

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

Anti-EGF Receptor Antibody, Unconjugated

RRID:AB_331707

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2232, RRID:AB_331707

Antibody Information

URL: http://antibodyregistry.org/AB_331707

Proper Citation: Cell Signaling Technology Cat# 2232, RRID:AB_331707

Target Antigen: EGF Receptor

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10202064, AB_10692644, AB_331707, AB_823483.

Antibody Name: Anti-EGF Receptor Antibody, Unconjugated

Description: This unknown targets EGF Receptor

Target Organism: rat, mouse, human

Antibody ID: AB_331707

Vendor: Cell Signaling Technology

Catalog Number: 2232

Record Creation Time: 20250820T031014+0000

Record Last Update: 20250820T153202+0000

Ratings and Alerts

No rating or validation information has been found for Anti-EGF Receptor Antibody, Unconjugated.

No alerts have been found for Anti-EGF Receptor Antibody, Unconjugated.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Asmanidou S, et al. (2026) BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. *Cell death & disease*, 17(1), 187.

Lam D, et al. (2026) Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function. *Cancers*, 18(3).

Savoca A, et al. (2026) Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. *Molecular cancer therapeutics*, 25(7), 1157.

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. *Cancer cell*, 44(6), 1218.

Buzo K, et al. (2026) WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. *EMBO molecular medicine*, 18(6), 2322.

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. *Cancer research*, 85(9), 1611.

Albert V, et al. (2024) HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. *International journal of molecular sciences*, 25(13).

Zarco N, et al. (2024) Resistance to spindle inhibitors in glioblastoma depends on STAT3 and therapy induced senescence. *iScience*, 27(12), 111311.

Zwirner S, et al. (2024) First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. *Cell*, 187(7), 1666.

Roper N, et al. (2024) Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. *Cancer research communications*, 4(2), 337.

Gan WL, et al. (2024) Hepatocyte-macrophage crosstalk via the PGRN-EGFR axis modulates ADAR1-mediated immunity in the liver. *Cell reports*, 43(7), 114400.

Manzar N, et al. (2024) An integrative proteomics approach identifies tyrosine kinase KIT as a therapeutic target for SPINK1-positive prostate cancer. *iScience*, 27(3), 108794.

Riley AK, et al. (2024) The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes. *iScience*, 27(8), 110499.

Bahnassy S, et al. (2023) Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer. *bioRxiv* : the preprint server for biology.

Pan Y, et al. (2023) KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. *Cancer cell*, 41(1), 88.

Song WM, et al. (2023) Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. *iScience*, 26(2), 106064.

Bahnassy S, et al. (2023) Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer. *Endocrinology*, 164(12).

Hertel A, et al. (2022) USP32-regulated LAMTOR1 ubiquitination impacts mTORC1 activation and autophagy induction. *Cell reports*, 41(10), 111653.

Kenchappa RS, et al. (2022) Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma. *Cell reports*, 39(12), 110991.

Bosse KR, et al. (2022) Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. *Cancer discovery*, 12(12), 2800.